PRESS CONTACT
Dr. Jürgen Krauter
Head of Communications
Nutrition & Care
juergen.krauter@evonik.com
SPECIALIZED PRESS CONTACT
Stephen Allan
External Communications
Health Care
stephen.allan@evonik.com
Press release
Products
October 16, 2019
Evonik announces price increase for amino acids used in pharmaceutical and human nutrition applications

Evonik Nutrition & Care GmbH will implement a price increase of up to 10% for its amino acid product portfolio for all applications sold via the business line Health Care. The price increase will take effect on December 15th, 2019.

The price adjustment reflects increasing market requirements, with Evonik having made significant investments to further enhance product quality, supply security and services.

Further information
  • Amino acids for pharmaceutical applications
  • Amino acids for human nutrition applications
Company information

Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-oriented innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik's corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world. In fiscal 2018, the enterprise with more than 32,000 employees generated sales of €13.3 billion and an operating profit (adjusted EBITDA) of €2.15 billion from continuing operations.

About Nutrition & Care

The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 8,200 employees, and generated sales of around €4.6 billion in 2018.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.

Attachments

  • Original document
  • Permalink

Disclaimer

Evonik Industries AG published this content on 16 October 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 October 2019 06:17:04 UTC